Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. has reported developments tied to its history as a clinical-stage biopharmaceutical company developing small molecule therapeutics for immune-mediated diseases. Company updates have centered on zetomipzomib, a selective immunoproteasome inhibitor evaluated in autoimmune hepatitis and other chronic immune-mediated diseases, including clinical data presentations and FDA regulatory correspondence.
Other recurring developments include operating and financial results, cost-containment measures, strategic review actions, the completed sale of Sec61-based discovery and development assets including KZR-261 to Enodia Therapeutics, and corporate transaction matters following Aurinia-related acquisition activity and Nasdaq delisting procedures.
Kezar Life Sciences announced positive results from the MISSION Phase 2 trial of zetomipzomib, a selective immunoproteasome inhibitor for lupus nephritis (LN). In 17 patients, the overall renal response rate (ORR) reached 64.7% at the end of treatment, improving to 88.2% during follow-up. Additionally, 35.3% achieved complete renal responses (CRR) at the end of treatment, increasing to 41.2% by study's end. The treatment demonstrated a favorable safety profile with no new safety signals. Kezar is planning further studies to explore zetomipzomib's full therapeutic potential.
Kezar Life Sciences (KZR) announced its participation at the ASN Kidney Week 2022 Annual Meeting in Orlando, FL, from November 3-6, where four posters will be presented. Key highlights include the full data from the Phase 2 MISSION trial on Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for lupus nephritis, demonstrating positive results from all 17 evaluable patients. More detailed findings will be shared beyond the abstract during the event, enhancing knowledge about KZR-616's potential in treating autoimmune diseases.
Kezar Life Sciences, Inc. (NASDAQ: KZR) announced the grant of nonqualified stock options for 85,000 shares to three employees, with an exercise price of $8.80 per share, matching the closing price on October 3, 2022. These options are part of an inducement award related to employment and will vest over four years. Kezar focuses on breakthrough treatments for immune-mediated and oncologic disorders, with products like Zetomipzomib and KZR-261 in clinical trials.
Kezar Life Sciences has received FDA clearance for its Investigational New Drug (IND) application of zetomipzomib (KZR-616) aimed at treating autoimmune hepatitis (AIH), a chronic condition affecting approximately 140,000 individuals in the U.S. This approval initiates the PORTOLA trial, a Phase 2a study focusing on the drug's safety and efficacy for patients not responding to standard treatments. The study aims to enroll 24 patients and evaluate treatment outcomes by measuring liver enzyme levels.
Kezar Life Sciences (KZR) announced the presentation of three posters at the American College of Rheumatology (ACR) Convergence 2022 from November 10-14 in Philadelphia, PA. The key presentation will feature full data from the Phase 2 MISSION study, where all 17 patients completed a 37-week trial of Zetomipzomib (KZR-616). Additional findings will be shared that are not included in the abstract. The presentations will cover topics like health-related quality of life in lupus nephritis patients and healthcare cost management.
Kezar Life Sciences, Inc. announced the granting of a nonqualified stock option to one employee for 18,000 shares at an exercise price of $10.10 per share. This grant aligns with the closing price on September 1, 2022. The stock option will vest over four years, starting with 25% after the first anniversary of employment, followed by monthly vesting. This award is part of the company's 2022 Inducement Plan, aimed at attracting talent in its pursuit of innovative treatments for immune-mediated and oncologic disorders.
Kezar Life Sciences (NASDAQ: KZR), a biotechnology firm focused on innovative treatments for immune-mediated and oncologic disorders, announced that its Co-founder and Chief Scientific Officer, Christopher Kirk, PhD, will present at three upcoming investor conferences in September 2022. The events include the Wells Fargo Healthcare Conference in Boston on September 8, H.C. Wainwright's Global Investment Conference in New York on September 13, and Morgan Stanley's Global Healthcare Conference in New York on September 14. Webcasts will be available on the company's website post-event.
Kezar Life Sciences (NASDAQ: KZR) announced positive topline results from the MISSION Phase 2 trial of zetomipzomib for lupus nephritis, showing that 64.7% of patients achieved a 50% reduction in proteinuria. The company appointed Nick Mordwinkin as Chief Business Officer, enhancing its leadership team. Financially, Kezar reported cash, cash equivalents, and marketable securities totaling $306.8 million as of June 30, 2022, up from $208.4 million at the end of 2021. However, the company incurred a net loss of $16.2 million for the quarter.
Kezar Life Sciences announced the grant of stock options to its newly appointed Chief Business Officer, Nick Mordwinkin, totaling 200,000 shares at an exercise price of $9.35, equal to the stock's closing price on August 1, 2022. An additional employee received 60,000 shares under similar conditions. The options will vest over four years, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing key personnel. Kezar focuses on treatments for immune-mediated and oncologic disorders, advancing candidates like Zetomipzomib and KZR-261.
Kezar Life Sciences (NASDAQ: KZR) announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer. Dr. Mordwinkin brings over a decade of experience in healthcare, previously at Gilead Sciences and Ultragenyx Pharmaceutical. His expertise will shape Kezar's business development strategy as the company advances its lead candidates, zetomipzomib and KZR-261. Additionally, Kezar reported an unaudited cash position of approximately $307 million as of June 30, 2022, positioning it well for future growth.